Kenilworth

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress

Tokyo, September 29, 2019: Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European…

5 years ago

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA

For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not…

5 years ago

Sun Pharma and China Medical System Holdings enter into a License Agreement for Tildrakizumab in Greater China

Relationship gives Sun Pharma access to Greater China market for Tildrakizumab China to become a key market in future with…

5 years ago

Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting

Tokyo, May 16, 2019: Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its…

6 years ago

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA

In Combination with KEYTRUDA as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma Tokyo, August 05,…

6 years ago

MSD, Ferring complete clinical trial for Postpartum Haemorrhage

Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the leading direct cause of maternal mortality worldwide. Delhi, March 12,…

7 years ago